← Back to Home

Putting Blood-Forming Cells Back in Charge: All 28 Participants in RM001 Phase II Trial Achieve Transfusion Independence

Reforgene Medicine announced that all 28 participants in the pivotal trial of its gene-editing therapy RM001 have stopped relying on transfusions, with each followed for more than a year. This adds clinical evidence for the strategy of reactivating fetal hemoglobin, but full data and long-term safety remain to be examined.

By SURL BioNews

For patients with transfusion-dependent β-thalassemia, regular transfusions sustain daily life but also bring the burden of long-term iron accumulation. If their own blood-forming cells could consistently produce enough hemoglobin, the focus of treatment could shift. Reforgene Medicine recently announced that all 28 participants in the pivotal Phase II trial of its investigational gene-editing therapy RM001 achieved transfusion independence, with each followed for more than a year.

The trial began in 2025. According to the company’s announcement and an October 21 report by healthcare industry media outlet VCBeat, all 28 participants remained transfusion-independent as of October 2026. However, “followed for more than a year” does not mean that every participant has gone a full consecutive year without transfusions; the announcement did not list individual dates for stopping transfusions or fully describe the criteria used to assess efficacy endpoints.

RM001 involves collecting patients’ own CD34-positive hematopoietic stem and progenitor cells, editing the HBG1/2 promoters outside the body using CRISPR technology, and then infusing the cells back into the patients. These promoters act like switches controlling γ-globin production; modifying them is intended to increase fetal hemoglobin production and compensate for the deficit caused by insufficient functional β-globin.

This design draws on naturally occurring protective variants in humans that allow fetal hemoglobin concentrations to remain elevated over the long term. The company hopes this will establish sustained, effective blood formation. However, differences in the mechanism of action alone cannot establish that RM001 is more effective or safer than other therapies; that judgment still requires clinical evidence.

Earlier studies provide a longer observation window. The company said that 47 people in total have received treatment across investigator-initiated trials and Phase I and Phase II studies, all achieving transfusion independence, with follow-up extending to five years at the longest. These 47 people include the 28 participants in the latest announcement; five years is the longest follow-up recorded across the development program and cannot be applied to every participant.

On safety, the company said that through this follow-up, no serious adverse events related to the RM001 product had been reported, and no hepatic veno-occlusive disease, deaths, treatment discontinuations, or malignancies had been observed. These findings provide preliminary support, but “no product-related serious adverse events” does not mean there were no other adverse reactions during treatment. The limited number of participants and duration of follow-up are also insufficient to rule out rare or later-emerging risks.

The information currently available for verification remains centered on company disclosures. VCBeat’s report also relays the same results and does not constitute independent verification of efficacy. The announcement did not provide complete patient-level data or comparative trial results, so relative efficacy cannot yet be determined from it. RM001 has not yet received marketing approval. The significance of this development is that more patients have maintained transfusion independence; how long this improvement can last and which patients it applies to remain questions for subsequent complete data to answer.

References

  1. Reforgene Medicine
  2. VCBeat